Taysha Gene Therapies Inc (NASDAQ:TSHA) — Market Cap & Net Worth
Market Cap & Net Worth: Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc (NASDAQ:TSHA) has a market capitalization of $1.68 Billion ($1.68 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6669 globally and #2081 in its home market, demonstrating a 0.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Taysha Gene Therapies Inc's stock price $5.86 by its total outstanding shares 287361020 (287.36 Million). See Taysha Gene Therapies Inc (TSHA) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Taysha Gene Therapies Inc Market Cap History: 2020 to 2026
Taysha Gene Therapies Inc's market capitalization history from 2020 to 2026. Data shows change from $7.63 Billion to $1.68 Billion (-21.44% CAGR).
Index Memberships
Taysha Gene Therapies Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.07% | #185 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #753 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.10% | #115 of 263 |
Weight: Taysha Gene Therapies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Taysha Gene Therapies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Taysha Gene Therapies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
161.72x
Taysha Gene Therapies Inc's market cap is 161.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $649.44 Million | $2.50 Million | -$166.01 Million | 259.57x | N/A |
| 2023 | $508.63 Million | $15.45 Million | -$111.57 Million | 32.92x | N/A |
| 2024 | $497.13 Million | $8.33 Million | -$89.30 Million | 59.66x | N/A |
| 2025 | $1.58 Billion | $9.77 Million | -$109.00 Million | 161.72x | N/A |
Competitor Companies of TSHA by Market Capitalization
Companies near Taysha Gene Therapies Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Taysha Gene Therapies Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Taysha Gene Therapies Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Taysha Gene Therapies Inc's market cap moved from $7.63 Billion to $ 1.68 Billion, with a yearly change of -21.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.68 Billion | +6.55% |
| 2025 | $1.58 Billion | +217.92% |
| 2024 | $497.13 Million | -2.26% |
| 2023 | $508.63 Million | -21.68% |
| 2022 | $649.44 Million | -80.60% |
| 2021 | $3.35 Billion | -56.10% |
| 2020 | $7.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Taysha Gene Therapies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.68 Billion USD |
| MoneyControl | $1.68 Billion USD |
| MarketWatch | $1.68 Billion USD |
| marketcap.company | $1.68 Billion USD |
| Reuters | $1.68 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 … Read more